Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Bausch Health Companies Inc. Common Stock (TSX:BHC)

6.860 -0.600 (-8.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch Health Companies Inc. Common Stock

< Previous 1 2 3 4 Next >
Bausch Health Unveils "Looking Forward" - A New DTC Television Campaign for Seasonal Affective Disorder (SAD)
Via ACCESSWIRE
FDA Approves Cabtreo(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide) Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older
Via ACCESSWIRE
New Analysis Indicates That a Majority of Overt Hepatic Encephalopathy (OHE) Patients May Face Delays in Treatment Initiation and Gaps During Treatment for Access to Treatment Indicated to Reduce Risk for OHE Recurrence
Via ACCESSWIRE
Bausch Health to Announce Third-Quarter 2023 Results on Nov. 2
Via ACCESSWIRE
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase in Chronic Liver Disease and Cirrhosis-Related Deaths Marking These as Ninth Leading Cause of Death in U.S.
Via ACCESSWIRE
Salix Pharmaceuticals Partners with Bellamy Young
Via ACCESSWIRE
League of United Latin American Citizens (LULAC) Joins OraPharma in the Fight Against Gum Disease
Via ACCESSWIRE
Ortho Dermatologics Announces 2023 Aspire Higher Scholarship Recipients
Via ACCESSWIRE
Bausch Health's Bausch + Lomb Announces Completion of the Acquisition of XIIDRA(R)
Via ACCESSWIRE
Bausch Health Announces CFO Transition Plan
Via ACCESSWIRE
New Bausch Health Treatment PrUCERIS(R) (budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults
Via ACCESSWIRE
Bausch Health's Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA(R)
Via ACCESSWIRE
Salix Announces 2023 Gastrointestinal Health Scholars Program Winners
Via ACCESSWIRE
Salix to Present Data from XIFAXAN(R) (Rifaximin) Clinical Research at EASL's International Liver Congress(TM) 2023
Via ACCESSWIRE
Bausch Health Announces 2023 Annual Meeting of Shareholder Results
Via ACCESSWIRE
Bausch Health's Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA(R)
Via ACCESSWIRE
Bausch Health Announces Second-Quarter 2023 Results, Other Key Updates From the Quarter, and Raises Full-Year 2023 Revenue Outlook
Via ACCESSWIRE
Bausch Health to Announce Second-Quarter 2023 Results on Aug. 3
Via ACCESSWIRE
OraPharma to Participate in the First-Ever Research and Technology Pavilion Sponsored by Pacific Dental Services(R) at the American Dental Hygienists' Association (ADHA(R)) Annual Conference
Via ACCESSWIRE
Bausch Health Enters Into $600 Million Financing Facility With KKR
Via ACCESSWIRE
Salix Pharmaceuticals to Deliver Podium Presentation at Digestive Disease Week(R) 2023
Via ACCESSWIRE
Bausch Health Announces First-Quarter 2023 Results
Via ACCESSWIRE
Ortho Dermatologics Announces U.S. Food and Drug Administration New Drug Application Filing Acceptance for Investigational Acne Treatment IDP-126 Gel
Via ACCESSWIRE
Bausch Health’s Bausch + Lomb to Acquire Novartis’ XIIDRA(R)
Via ACCESSWIRE
Bausch Health Responds to Norwich's ANDA Tentative Approval and Lawsuit Against United States Food and Drug Administration
Via ACCESSWIRE
New Clinical Study Suggests the Use of OraPharma’s ARESTIN(R) (minocycline HCl) Microspheres, 1mg May Decrease Certain Pathogens in Adults with Periodontitis
Via ACCESSWIRE
U.S. District Court Upholds Final Judgment for XIFAXAN(R) 550 mg That Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
Via ACCESSWIRE
Bausch Health Observes Mental Health Awareness Month
Via ACCESSWIRE
Salix Partners with the Colorectal Cancer Alliance on Community Screening Program
Via ACCESSWIRE
New Artificial Intelligence Tool Can Diagnose Colon Cancer
A new artificial intelligence (AI) model developed by Harvard Medical School and Taiwan’s National Cheng Kung University could provide much-needed clarity to clinicians presenting prognoses and... 
Via PressReach
Topics Artificial Intelligence Death
Exposures Artificial Intelligence Death Product Safety
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.